Early and Late Leaflet Thrombosis After Transcatheter Aortic Valve Replacement.


Journal

Circulation. Cardiovascular interventions
ISSN: 1941-7632
Titre abrégé: Circ Cardiovasc Interv
Pays: United States
ID NLM: 101499602

Informations de publication

Date de publication:
02 2019
Historique:
entrez: 9 2 2019
pubmed: 9 2 2019
medline: 26 2 2020
Statut: ppublish

Résumé

The occurrence and clinical impact of untreated subclinical leaflet thrombosis beyond 1 year after transcatheter aortic valve replacement still remain unclear. In a multicenter transcatheter aortic valve replacement registry, we analyzed data from 485 patients who underwent 4-dimensional multidetector computed tomography posttranscatheter aortic valve replacement performed to survey hypoattenuated leaflet thickening with reduced leaflet motion compatible with thrombus at a median of 3 days, 6 months, 1 year, 2 years, and 3 years. Incidence, predictors, and clinical outcomes of early (median 3 days) and late (>30 days) leaflet thrombosis were assessed. Additional anticoagulation was not administered because of subclinical findings at the time of computed tomography in all patients. Early leaflet thrombosis occurred in 45 (9.3%) of 485 patients. Mean pressure gradient at discharge was higher in patients with early leaflet thrombosis than in those without. Independent predictors of early leaflet thrombosis in balloon-expandable prostheses were low-flow, low-gradient aortic stenosis, severe prosthesis-patient mismatch, and 29-mm prostheses. No predictors could be identified for self-expanding prosthesis. Cumulative event rates of death, stroke, or rehospitalization for heart failure over 2 years were 10.7% and 16.9% in patients with and without early leaflet thrombosis, respectively ( P=0.63). Late leaflet thrombosis occurred late up to 3 years, and male sex and paravalvular leak less than mild were independent predictors. Untreated early leaflet thrombosis did not affect the cumulative event rates of death, stroke, and rehospitalization for heart failure. Late leaflet thrombosis was newly detected during 3-year follow-up. Visual Overview: A visual overview is available for this article.

Sections du résumé

BACKGROUND
The occurrence and clinical impact of untreated subclinical leaflet thrombosis beyond 1 year after transcatheter aortic valve replacement still remain unclear.
METHODS AND RESULTS
In a multicenter transcatheter aortic valve replacement registry, we analyzed data from 485 patients who underwent 4-dimensional multidetector computed tomography posttranscatheter aortic valve replacement performed to survey hypoattenuated leaflet thickening with reduced leaflet motion compatible with thrombus at a median of 3 days, 6 months, 1 year, 2 years, and 3 years. Incidence, predictors, and clinical outcomes of early (median 3 days) and late (>30 days) leaflet thrombosis were assessed. Additional anticoagulation was not administered because of subclinical findings at the time of computed tomography in all patients. Early leaflet thrombosis occurred in 45 (9.3%) of 485 patients. Mean pressure gradient at discharge was higher in patients with early leaflet thrombosis than in those without. Independent predictors of early leaflet thrombosis in balloon-expandable prostheses were low-flow, low-gradient aortic stenosis, severe prosthesis-patient mismatch, and 29-mm prostheses. No predictors could be identified for self-expanding prosthesis. Cumulative event rates of death, stroke, or rehospitalization for heart failure over 2 years were 10.7% and 16.9% in patients with and without early leaflet thrombosis, respectively ( P=0.63). Late leaflet thrombosis occurred late up to 3 years, and male sex and paravalvular leak less than mild were independent predictors.
CONCLUSIONS
Untreated early leaflet thrombosis did not affect the cumulative event rates of death, stroke, and rehospitalization for heart failure. Late leaflet thrombosis was newly detected during 3-year follow-up. Visual Overview: A visual overview is available for this article.

Identifiants

pubmed: 30732472
doi: 10.1161/CIRCINTERVENTIONS.118.007349
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e007349

Auteurs

Ryo Yanagisawa (R)

Department of Cardiology (R.Y., M.T., F. Yashima, T.A., K.F., K.H.), Keio University School of Medicine, Tokyo, Japan.

Makoto Tanaka (M)

Department of Cardiology (R.Y., M.T., F. Yashima, T.A., K.F., K.H.), Keio University School of Medicine, Tokyo, Japan.

Fumiaki Yashima (F)

Department of Cardiology (R.Y., M.T., F. Yashima, T.A., K.F., K.H.), Keio University School of Medicine, Tokyo, Japan.

Takahide Arai (T)

Department of Cardiology (R.Y., M.T., F. Yashima, T.A., K.F., K.H.), Keio University School of Medicine, Tokyo, Japan.

Masahiro Jinzaki (M)

Department of Diagnostic Radiology (M.J.), Keio University School of Medicine, Tokyo, Japan.

Hideyuki Shimizu (H)

Department of Cardiovascular Surgery (H.S.), Keio University School of Medicine, Tokyo, Japan.

Keiichi Fukuda (K)

Department of Cardiology (R.Y., M.T., F. Yashima, T.A., K.F., K.H.), Keio University School of Medicine, Tokyo, Japan.

Yusuke Watanabe (Y)

Teikyo University School of Medicine, Tokyo, Japan (Y.W.).

Toru Naganuma (T)

New Tokyo Hospital, Matsudo, Japan (T.N.).

Akihiro Higashimori (A)

Kishiwada Tokushukai Hospital, Osaka, Japan (A.H.).

Kazuki Mizutani (K)

Osaka City General Hospital, Japan (K.M.).

Motoharu Araki (M)

Saiseikai Yokohama-City Eastern Hospital, Tsurumi, Japan (M.A.).

Norio Tada (N)

Sendai Kousei Hospital, Japan (N.T.).

Futoshi Yamanaka (F)

Shonan Kamakura General Hospital, Japan (F. Yamanaka).

Toshiaki Otsuka (T)

Department of Hygiene and Public Health and Center for Clinical Research, Nippon Medical School, Tokyo, Japan (T.O.).

Masanori Yamamoto (M)

Toyohashi Heart Center, Japan (M.Y.).
Nagoya Heart Center, Japan (M.Y.).

Kentaro Hayashida (K)

Department of Cardiology (R.Y., M.T., F. Yashima, T.A., K.F., K.H.), Keio University School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH